176499 Acceptability of a daily pill as a pre-exposure prophylaxis for HIV

Monday, October 27, 2008

Greg Guest, PhD , Behavioural and Biomedical Research Department, Family Health International, Research Triangle Park, NC
Dominick Shattuck, PhD , Behavioural and Biomedical Research Department, Family Health International, Research Triangle Park, NC
Laura Johnson , Behavioural and Biomedical Research Department, Family Health International, Research Triangle Park, NC
Betty Akumatey , University of Ghana, Legon, Legon, Ghana
Edith Clarke, MD , Ministry of Health, Accra, Ghana
Kathleen M. MacQueen, PhD, MPH , Family Health International, Research Triangle Park, NC
Background: With an effective HIV vaccine years away, attention has been directed to the development and testing of an oral chemo-prophylactic. For any intervention to be effective it must be acceptable within the target population. This paper describes the experiences of Ghanaian women at high risk for HIV enrolled in a safety and efficacy oral tenofovir HIV-prevention trial.

Methods: The behavioral study included structured surveys with 364 trial participants at enrollment and 12 monthly clinic visits during the year-long trial. In-depth interviews were conducted with 24 of the study participants midway through the trial. Growth curve analysis was used to analyze various aspects of participants' use of the study pill. Thematic analysis was carried out on the qualitative data.

Results: Self-reported pill adherence (“last 7 days”) exceeded 74% throughout the trial. At month 1, 31% of participants reported a problem with the pill in the survey. This number decreased steadily until month 6, when it stabilized at <4%. The most commonly reported problems were physical (61%) - mainly gastrointestinal issues, fatigue and dizziness – and did not differ between placebo/treatment groups (Peterson et al. 2007). Additional problems were: forgetting to take the pill (20%), traveling (8%), and swallowing the pill (5%). Qualitative data confirmed that most problems diminished over time, as side effects eased and women adapted the pill-taking routine into their daily lives.

Conclusion: Oral prophylaxis as a strategy for HIV-prevention was acceptable to women at risk for HIV in the study site, and acceptability of the method improved over time.

Learning Objectives:
1. Evaluate the acceptability of a daily pill for HIV prevention among women at high risk for HIV in Africa. 2. Identify potential barriers to acceptance and adherence of a daily chemo-prophylaxis. 3. Develop strategies for enhancing acceptability of a daily pill for HIV prevention.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I collected much of the data upon which the poster is based, and helped with the poster text.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

See more of: Special Topics in HIV-Related Care
See more of: HIV/AIDS